We are live on ! Find out more
INTS icon

Intensity Therapeutics

26 hedge funds and large institutions have $721K invested in Intensity Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 1

19% more capital invested

Capital invested by funds: $607K → $721K (+$115K)

0.06% less ownership

Funds ownership: 0.3%0.24% (-0.06%)

4% less funds holding

Funds holding: 2726 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
10
Reduced
1
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$121
Jane Street
27
Jane Street
New York
-$13.8K -1,796 Closed
HF
28
HRT Financial
New York
-$7K -996 Closed
XT
29
XTX Topco
Cayman Islands
-$7.54K -982 Closed
BFM
30
Boothbay Fund Management
New York
-$4.61K -600 Closed
CSS
31
Cubist Systematic Strategies
Connecticut
-$3.58K -467 Closed
Fidelity Investments
32
Fidelity Investments
Massachusetts
-$31 -4 Closed

INTS Hedge Fund Activity: Q3 2025 in Review

26 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q3 2025, worth a combined $721K — up 19% from $607K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of INTS and 5 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 10 added.

The largest buyer was Sentinus LLC, adding an estimated $80.6K. The largest seller was Jane Street, exiting entirely with an estimated $13.8K sold.

  • 26 institutional investors held Intensity Therapeutics (INTS) as of Q3 2025, down from 27 in Q2 2025.
  • Funds reported $721K of Intensity Therapeutics stock for Q3 2025, up 19% quarter-over-quarter.
  • 5 funds opened new Intensity Therapeutics positions in Q3 2025 and 6 closed out, a net change of -1 holder.
  • The largest Intensity Therapeutics buyer in Q3 2025 was Sentinus LLC, an estimated $80.6K added.
  • The largest Intensity Therapeutics seller in Q3 2025 was Jane Street, an estimated $13.8K sold.

Based on aggregated 13F filings for Q3 2025.